Hyderabad-based Aryastha Life Sciences, a leading Contract Research and Development Organisation in healthcare, has achieved a major milestone by successfully concluding its Series A funding with significant backing from Vessella Group, a prominent investor in India.

A strategic funding boost from Vessella positions Aryastha to reshape drug discovery and development in the pharmaceutical and biotech sectors. With a vision to provide exceptional solutions for unmet clinical needs, Aryastha leverages cutting-edge R&D infrastructure in India and plans expansion in the USA.

Aryastha aims to differentiate as a pioneer, utilising artificial intelligence (AI), advanced preclinical models derived from patient samples and  pluripotent stem cells  'Aryastha's Bio Solutions' for efficient drug screening. This innovative approach accelerates the clinical translatability of candidates, streamlining services across the value chain and addressing pharmaceutical industry challenges.

With cutting-edge facilities and a skilled team, Aryastha cultivates an environment of innovation. Partnering with Vessella Group offers a unique chance for impactful change in healthcare. Vessella's investment acknowledges outsourcing's significance in drug discovery and development, aligning with Aryastha's expertise. Guided by visionary leadership, Aryastha is poised to advance scientific solutions and provide quality healthcare services.